Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ira Mitchell

Internal Medicine Florence, AL Medical Doctor

NPI 1881776078 CMS profile 39485

2115 Cloyd Blvd, Suite 1, Florence, AL 35630

Open in the dashboard

General payments

$9,784

669 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ira Mitchell of Florence, AL is reported in the CMS Open Payments database as having received $9,784 across 669 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $883 49
2024 General $971 57
2023 General $1,617 107
2022 General $1,367 92
2021 General $1,727 125
2020 General $1,657 121
2019 General $1,561 118

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ira Mitchell
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Ira Mitchell were reported at $883. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Ira Mitchell Internal Medicine median Middle half National median
2019 $1,561 $159 $48–$570 $163
2020 $1,657 $119 $33–$402 $114
2021 $1,727 $135 $37–$521 $132
2022 $1,367 $141 $42–$496 $149
2023 $1,617 $149 $45–$519 $160
2024 $971 $154 $47–$537 $164
2025 $883 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,244 70 payments
  2. Lilly USA, LLC $808 60 payments
  3. AbbVie, Inc. $789 71 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $730 51 payments
  5. Merck Sharp & Dohme Corporation $724 44 payments
  6. Pfizer Inc. $673 49 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $513 32 payments
  8. GlaxoSmithKline, LLC. $461 31 payments
  9. Allergan Inc. $427 43 payments
  10. Novo Nordisk Inc $357 27 payments
  11. Other $3,058 191 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,777 667 payments
  2. Education $7 2 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $758 42 payments
  2. JARDIANCE $558 40 payments
  3. BELSOMRA $534 31 payments
  4. MOUNJARO $515 36 payments
  5. XIFAXAN $513 32 payments
  6. ELIQUIS $473 34 payments
  7. JANUVIA $465 28 payments
  8. VERQUVO $460 28 payments
  9. TRELEGY ELLIPTA $447 30 payments
  10. UBRELVY $409 36 payments
  11. Other $9,331 636 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 212 drugs

Part D claims

22,106

Median for Internal Medicine: 777

Drug cost

$1,260,206

Median for Internal Medicine: $73,373

Branded share of claims

24%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 284 $210,825
Jardiance Empagliflozin Brand 185 $132,977
Mounjaro Tirzepatide Brand 107 $117,823
Januvia Sitagliptin Phosphate Brand 101 $84,048
Ozempic Semaglutide Brand 51 $60,639
Janumet Sitagliptin Phos/Metformin Hcl Brand 76 $52,006
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 65 $44,295
Farxiga Dapagliflozin Propanediol Brand 46 $33,467
Xarelto Rivaroxaban Brand 43 $28,016
Entresto Sacubitril/Valsartan Brand 47 $25,281

The 10 drugs with the highest cost, of 212 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$193,851

Of which drugs: $4,427

Medicare patients

1,077

Average age 75

Services billed

3,122

618 women, 459 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Ischemic heart disease 43%
Diabetes 39%
COPD 31%
Depression 31%
Atrial fibrillation 30%
Heart failure 29%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent derived from cell cultures 90661 Office 112 112 $4,043
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 22 200 $132
Injection, ceftriaxone sodium, per 250 mg J0696 Office 12 24 $7

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $193
$193 107 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $115
$115 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $103
$103 46 —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $74
$74 — —
TRINTELLIX
  • Takeda Pharmaceuticals U.S.A., Inc. $49
$49 29 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

669 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record